Skip to main content

Research Repository

Advanced Search

The suboptimal fibrinolytic response in COVID-19 is dictated by high PAI-1.

Whyte, Claire S.; Simpson, Megan; Morrow, Gael B.; Wallace, Carol A.; Mentzer, Alexander J.; Knight, Julian C.; Shapiro, Susan; Curry, Nicola; Bagot, Catherine N.; Watson, Henry; Cooper, Jamie G.; Mutch, Nicola J.

Authors

Claire S. Whyte

Megan Simpson

Carol A. Wallace

Alexander J. Mentzer

Julian C. Knight

Susan Shapiro

Nicola Curry

Catherine N. Bagot

Henry Watson

Jamie G. Cooper

Nicola J. Mutch



Abstract

Severe COVID-19 disease is associated with thrombotic complications and extensive fibrin deposition. This study investigates whether the hemostatic complications in COVID-19 disease arise due to dysregulation of the fibrinolytic system. This prospective study analyzed fibrinolytic profiles of 113 patients hospitalized with COVID-19 disease with 24 patients with non-COVID-19 respiratory infection and healthy controls. Antigens were quantified by Ella system or ELISA, clot lysis by turbidimetric assay, and plasminogen activator inhibitor-1 (PAI-1)/plasmin activity using chromogenic substrates. Clot structure was visualized by confocal microscopy. PAI-1 and its cofactor, vitronectin, are significantly elevated in patients with COVID-19 disease compared with those with non-COVID-19 respiratory infection and healthy control groups. Thrombin activatable fibrinolysis inhibitor and tissue plasminogen activator were elevated in patients with COVID-19 disease relative to healthy controls. PAI-1 and tissue plasminogen activator (tPA) were associated with more severe COVID-19 disease severity. Clots formed from COVID-19 plasma demonstrate an altered fibrin network, with attenuated fiber length and increased branching. Functional studies reveal that plasmin generation and clot lysis were markedly attenuated in COVID-19 disease, while PAI-1 activity was elevated. Clot lysis time significantly correlated with PAI-1 levels. Stratification of COVID-19 samples according to PAI-1 levels reveals significantly faster lysis when using the PAI-1 resistant (tPA) variant, tenecteplase, over alteplase lysis. This study shows that the suboptimal fibrinolytic response in COVID-19 disease is directly attributable to elevated levels of PAI-1, which attenuate plasmin generation. These data highlight the important prognostic potential of PAI-1 and the possibility of using pre-existing drugs, such as tenecteplase, to treat COVID-19 disease and potentially other respiratory diseases.

Citation

WHYTE, C.S., SIMPSON, M., MORROW, G.B., WALLACE, C.A., MENTZER, A.J., KNIGHT, J.C., SHAPIRO, S., CURRY, N., BAGOT, C.N., WATSON, H., COOPER, J.G. and MUTCH, N.J. 2022. The suboptimal fibrinolytic response in COVID-19 is dictated by high PAI-1. Journal of thrombosis and haemostasis [online], 20(10), pages 2394-2406. Available from: https://doi.org/10.1111/jth.15806

Journal Article Type Article
Acceptance Date Aug 30, 2022
Online Publication Date Sep 19, 2023
Publication Date Oct 31, 2022
Deposit Date Jul 25, 2023
Publicly Available Date Jul 25, 2023
Journal Journal of thrombosis and haemostasis
Print ISSN 1538-7933
Electronic ISSN 1538-7836
Publisher Wiley
Peer Reviewed Peer Reviewed
Volume 20
Issue 10
Pages 2394-2406
DOI https://doi.org/10.1111/jth.15806
Keywords COVID-19; Fibrin; Fibrinolysis; PAI-1; Vitronectin
Public URL https://rgu-repository.worktribe.com/output/2010403
Additional Information This article has been published with separate supporting information. This supporting information has been incorporated into a single file on this repository and can be found at the end of the file associated with this output.

Files

WHYTE 2022 The suboptimal fibrinolytic (VOR) (5.4 Mb)
PDF

Publisher Licence URL
https://creativecommons.org/licenses/by/4.0/

Copyright Statement
© 2022 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis.





You might also like



Downloadable Citations